Skin infections are a common reason for physician and emergency department (ED) visits. Community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) is now the most common known etiology of skin and soft tissue infections in most places in the United States [1]. The rise of CA-MRSA infections has resulted in an increase of non–β-lactam antibiotic therapy for skin infection. Commonly, these non–β-lactam therapies are combined with rifampin [2,3], based on the assumption that synergistic therapy with rifampin results in improved clinical efficacy.